FDA Bars New Patients From Avandia Study
The agency said Wednesday it had placed a “partial clinical hold” on the postmarketing trial and directed the drugmaker to update investigators, review boards and ethical committees involved in the study on safety concerns of Avandia raised at an FDA advisory committee meeting on July 14.
Patients already enrolled in the study...
Already a subscriber? Click here to login